Health & Fitness
Health and Fitness
Health and Fitness
Wed, February 29, 2012Tue, February 28, 2012Mon, February 27, 2012Sat, February 25, 2012Fri, February 24, 2012Thu, February 23, 2012Wed, February 22, 2012Tue, February 21, 2012Mon, February 20, 2012Sat, February 18, 2012Fri, February 17, 2012Thu, February 16, 2012Wed, February 15, 2012Halozyme Therapeutics to Present at the CITI 2012 Global Healthcare Conference
Published in Health and Fitness on Wednesday, February 22nd 2012 at 13:14 GMT by Market Wire
Halozyme Therapeutics to Present at the CITI 2012 Global Healthcare Conference -- SAN DIEGO, Feb. 22, 2012 /PRNewswire/ --
Halozyme Therapeutics to Present at the CITI 2012 Global Healthcare Conference
SAN DIEGO, Feb. 22, 2012 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: [ HALO ]) will be presenting at the Citi 2012 Global Healthcare Conference in New York on Wednesday, February 29, 2012 at 11:00 a.m. ET / 8:00 a.m. PT.Kurt Gustafson, Chief Financial Officer, Halozyme Therapeutics, will provide a corporate overview.
(Logo: [ http://photos.prnewswire.com/prnh/20100302/LA63139LOGO ])
The presentation will be webcast through the "Investors" section of Halozyme's corporate website at [ www.halozyme.com ], and a recording will be made available for 90 days following the event. To access the live webcast, please log on to Halozyme's website approximately fifteen minutes prior to the presentation to register and download any necessary audio software.
About Halozyme
Halozyme Therapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative products that advance patient care. With a diversified portfolio of enzymes that target the extracellular matrix, the Company's research focuses primarily on a family of human enzymes, known as hyaluronidases, that increase the absorption and dispersion of biologics. Halozyme's pipeline addresses therapeutic areas, such as diabetes, oncology and dermatology that have significant unmet medical need. The Company markets HYLENEX® recombinant (hyaluronidase human injection) and has partnerships with Roche, Baxter, ViroPharma and Intrexon. Halozyme is headquartered in San Diego, CA. For more information on how we are innovating, please visit our corporate website at [ www.halozyme.com ].
Media/Investor Contact:
Anne Erickson
Executive Director
Halozyme Therapeutics
858-704-8264
[ aerickson@halozyme.com ]
SOURCE Halozyme Therapeutics, Inc.
[ Back to top ] RELATED LINKS
[ http://www.halozyme.com ]
